Last reviewed · How we verify
ANKTIVA (nogapendekin alfa inbakicept-pmln)
ANKTIVA (generic name: nogapendekin alfa inbakicept-pmln) is a drug developed by ALTOR BIOSCIENCE, LLC, AN INDIRECT WHOLLY-OWNED SU. It is currently FDA-approved.
At a glance
| Generic name | nogapendekin alfa inbakicept-pmln |
|---|---|
| Sponsor | ALTOR BIOSCIENCE, LLC, AN INDIRECT WHOLLY-OWNED SU |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
- Dysuria
- Hematuria
- Urinary Frequency
- Micturition Urgency
- Urinary Tract Infection
- Musculoskeletal Pain
- Chills
- Pyrexia
- Fatigue
- Nausea
- Bladder Irritation
- Diarrhea
Serious adverse events
- Hematuria
- Cardiac Arrest
Key clinical trials
- A Pilot Trial of N-803 in Patients With Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Previously Treated With Adoptive Cellular Therapy (EARLY/Phase 1)
- Phase 3 Randomized, Blinded, Placebo-Controlled Study Evaluating Nogapendekin Alfa Inbakicept and iNKT Cells In Critically Ill Adults With Severe Community-Acquired Pneumonia With or Without Sepsis/Ac (Phase 3)
- Interleukin-15 to Promote Post-ART Control of HIV (Phase 2)
- Phase 2 Study Evaluating Nogapendekin Alfa Inbakicept and iNKT Cells in Critically Ill Adults With Severe Community-Acquired Pneumonia With or Without Sepsis/Acute Respiratory Distress Syndrome. (Phase 2)
- Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zabadinostat in Combination With Gemcitabine and Nab-Paclitaxel for Participants With Borderline Resecta (Phase 1)
- A Phase 2 Trial of PD-L1 t-haNK, NAI IL-15 Superagonist (Anktiva), and Cetuximab for Immunotherapy-treated Patients With Recurrent, Metastatic HNSCC (QUILT-505) (Phase 2)
- A Phase II, Single-Center, Open-Label Study of First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer (FLINN) (Phase 2)
- Open-label, Phase 1 Study of CD19 t-haNK as a Single Agent and in Combination With an IL-15 Superagonist (N-803) and Rituximab in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma. (Phase 1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ANKTIVA CI brief — competitive landscape report
- ANKTIVA updates RSS · CI watch RSS
- ALTOR BIOSCIENCE, LLC, AN INDIRECT WHOLLY-OWNED SU portfolio CI
Frequently asked questions about ANKTIVA
What is ANKTIVA?
ANKTIVA (nogapendekin alfa inbakicept-pmln) is a pharmaceutical drug developed by ALTOR BIOSCIENCE, LLC, AN INDIRECT WHOLLY-OWNED SU.
Who makes ANKTIVA?
ANKTIVA is developed and marketed by ALTOR BIOSCIENCE, LLC, AN INDIRECT WHOLLY-OWNED SU (see full ALTOR BIOSCIENCE, LLC, AN INDIRECT WHOLLY-OWNED SU pipeline at /company/altor-bioscience-llc-an-indirect-wholly-owned-su).
What is the generic name of ANKTIVA?
nogapendekin alfa inbakicept-pmln is the generic (nonproprietary) name of ANKTIVA.
What development phase is ANKTIVA in?
ANKTIVA is FDA-approved (marketed).
What are the side effects of ANKTIVA?
Common side effects of ANKTIVA include Dysuria, Hematuria, Urinary Frequency, Micturition Urgency, Urinary Tract Infection, Musculoskeletal Pain. Serious adverse events: Hematuria, Cardiac Arrest.
Related
- Manufacturer: ALTOR BIOSCIENCE, LLC, AN INDIRECT WHOLLY-OWNED SU — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing